Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pediatric

The Power of Advocacy

Blair Solow, MD  |  January 10, 2022

In 1916, a handful of conservation advocates successfully lobbied Congress to create the National Park Service, which now protects more than 85 million acres of U.S. land. Dedicated rheumatology advocacy has lasting effects, too, as evidenced by several policy wins in 2021 and efforts underway for 2022.

Filed under:Legislation & Advocacy Tagged with:ACR advocacyAdvocacyBuild Back Better ActLegislationMedicare reimbursement ratePediatric Subspecialty Loan Forgivenesspharmacy benefit managers (PBMs)Research Fundingstate legislationstep therapy legislationtelehealthWorkforce

The 2021 ACR Awards of Distinction & Distinguished Fellows

Patrice Fusillo  |  December 16, 2021

During ACR Convergence 2021 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care, announcing the recipients of the ACR’s 2021 Awards of Distinction, as well as the group of Distinguished Fellows. recognized for their contributions. Three pediatric rheumatologists and one pediatric fellow…

Filed under:AwardsProfessional Topics Tagged with:Dr. Alfredo AguirreDr. Alisa A. MuellerDr. Amanda E. NelsonDr. Anne R. BassDr. Brian M. FeldmanDr. Bryce A. BinstadtDr. Ida Dzifa DeyDr. Jacqueline MadisonDr. Jose U. ScherDr. Madelaine “Mattie” FeldmanDr. Mariana J. KaplanDr. Maximilian F. KonigDr. Michael H. WeismanDr. Naomi J. PatelDr. Philip SeoDr. Richard K. VeheDr. Rochelle L. CastilloDr. Roseanne F. ZhaoDr. Seoyoung C. KimDr. Sokratis ApostolidisDr. Stanley B. Cohen

The Transformative Power of Tragedy

Philip Seo, MD, MHS  |  December 16, 2021

On Sept. 11, 2001, I was at work. I had accepted a position as an assistant chief of service (ACS) for the Department of Medicine, which is Hopkins-speak for a hybrid position that involves all the administrative duties of a chief resident, plus the responsibility of an attending. For a year, I admitted patients to…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19

MIA Studio / shutterstock.com

Kawasaki Guideline Urges Treatment Intensification for Some Patients

Ruth Jessen Hickman, MD  |  December 16, 2021

A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:Kawasaki diseaseVasculitis

FDA Authorizes New Long-Acting, Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals

U.S. Food & Drug Administration   |  December 13, 2021

On Dec. 8, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). The product…

Filed under:Drug Updates Tagged with:AstraZenecacilgavimabCOVID-19EvusheldFDAmonoclonal antibodytixagevimabU.S. Food and Drug Administration (FDA)

Therapeutics for COVID-19: An update from ACR Convergence 2021

Lara C. Pullen, PhD  |  December 10, 2021

ACR CONVERGENCE 2021—Rheumatology patients who test positive for COVID-19 would benefit from early use of monoclonal antibodies, said Luis Ostrosky-Zeichner, MD, chief of the Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center (UTHealth), Houston, in a session about effective treatment options for COVID-19. Acknowledging that the SARS-CoV-2 virus has already…

Filed under:ACR ConvergenceBiologics/DMARDsMeeting Reports Tagged with:ACR Convergence 2021COVID-19

Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session

Samantha C. Shapiro, MD  |  December 9, 2021

Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLECOVID-19MIS-CPediatricpJIApolyarticular juvenile idiopathic arthritis

Bethany Marston, MD, Assumes Chair of Committee on Rheumatology Training & Workforce Issues

Gretchen Henkel  |  December 6, 2021

Noting that the pandemic has shifted what and how rheumatology trainees learn, Dr. Marston hopes the Committee on Rheumatology Training & Workforce Issues can work to understand current workforce needs and explore new educational opportunities.

Filed under:Education & TrainingProfiles Tagged with:Bethany MarstonCommittee on Rheumatology Training and Workforce IssuesWorkforce

Tofacitinib Yields Rapid & Sustained Improvement in JIA

Reuters Staff  |  December 3, 2021

NEW YORK (Reuters Health)—Tofacitinib significantly reduces the number of flares in children with polyarticular course juvenile idiopathic arthritis (JIA), according to the first phase-3 clinical trial to assess the efficacy of a Janus kinase (JAK) inhibitor in JIA. JIA is a heterogeneous group of chronic conditions with no known cause that develop before age 16…

Filed under:ConditionsRheumatoid Arthritis Tagged with:flareJIAjuvenile idiopathic arthritis (JIA)Tofacitinib

Advances in Rheumatology & Challenges that Remain Spotlighted in ACR Convergence 2021 Closing Session

Vanessa Caceres  |  December 2, 2021

The diverse topics, research & perspectives from this year’s ACR Convergence bring new insights for rheumatologists & all who care for their patients, according to speakers at the meeting’s Closing Session.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2021

  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 109
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences